logo
  

Novavax, Serum File For Emergency Use Authorization Of COVID-19 Vaccine Candidate In South Africa

Novavax, Inc. (NVAX) and Serum Institute of India Pvt. Ltd. announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate. If authorized, the vaccine will be manufactured by and commercialized by Serum Institute in South Africa under the brand name Covovax.

Novavax' vaccine has received authorizations of the vaccine in over 170 countries. The company expects to submit a request for EUA for the vaccine in the U.S. after one month in accordance with guidance from the FDA regarding submission of all EUA vaccines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Aerospace giant Boeing Co. (BA) on Wednesday reported fourth-quarter net loss attributable to Boeing shareholders of $4.16 billion or $7.02 per share, sharply narrower than $8.44 billion or $14.65 per share in the year-ago quarter. The 787 program recorded $3.5 billion pre-tax non-cash charge; focused... Telecom giant AT&T reported Wednesday a profit for the fourth quarter compared to a loss last year, primarily boosted by continuing customer growth in wireless, fiber and HBO Max, despite a 10 percent drop in revenues. Both adjusted earnings for the quarter and quarterly revenues also topped analysts' expectations. However, the company issued weak earnings and sales growth outlook for fiscal 2022. Bentley Motors, owned by German automaker Volkswagen AG, announced plans to develop its first-ever Battery-Powered Electric Vehicle or BEV in 2025. The British luxury carmaker also plans investment of around 2.5 billion pounds or $3.4 billion in sustainability over the next ten years. The company will develop and build the new vehicles in the UK plant in Crewe.
Follow RTT